Pharma Stocks
-
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Vertex Pharmaceuticals (VRTX 0.45%) is a biotech company that has steadily delivered growth to investors, thanks to its dominance in…
Read More » -
Russell 1000 Defensive Inclusion Might Change The Case For Investing In Royalty Pharma (RPRX)
Royalty Pharma plc (NasdaqGS:RPRX) was added to both the Russell 1000 Value-Defensive Index and the Russell 1000 Defensive Index on…
Read More » -
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
Stephen Carey, SVP & CFO of ANI Pharmaceuticals (ANIP 1.17%), reported the sale of 2,850 shares of common stock in…
Read More » -
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
Quick Read Cramer calls IBB the hottest group in the market, up 51% over the past year, with LLY completing…
Read More » -
Is UroGen Pharma (URGN) Undervalued Following FDA Clearance For UGN 501?
Why the UroGen Pharma Stock Move Is Tied to UGN-501 UroGen Pharma (URGN) is in focus after the U.S. Food…
Read More » -
Buy Senores Pharma; target of Rs 1640: Choice Institutional Equities
Choice Institutional Equities’s report on Senores Pharma SENORES is strengthening its position as a US-focused player through a differentiated product…
Read More » -
Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock a Buying Opportunity After a 44% Pullback?
When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off…
Read More » -
Royalty Pharma (RPRX) Could Be 2% Undervalued On Russell 1000 Defensive Index Addition
Royalty Pharma (RPRX) has just been added to both the Russell 1000 Value-Defensive Index and the Russell 1000 Defensive Index,…
Read More » -
Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals’ (AMRX) Investment Narrative?
Zambon and Amneal Pharmaceuticals recently announced that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion…
Read More » -
ARS Pharmaceuticals Announces CEO Succession
ARS Pharmaceuticals, Inc. Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company Donn…
Read More »